In a breast cancer cell line, filgotinib inhibited STAT3 phosphorylation; in combination with a histone deacetylase inhibitor, there was increased apoptosis in breast cancer cells as well as tumor growth inhibition in mice harboring breast cancer tumors[164]. The gene discussed is STAT3; the disease is breast carcinoma.